Kailera Therapeutics Insider Trades
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 5 · $326.75M
- Sales
- 0 · $0
- Shares bought / sold
- 20.42M / 0
- Net activity
- Net buying $326.8 million
Kailera Therapeutics insider activity
Over the last 12 months, Kailera Therapeutics insiders reported 15 transactions on SEC Form 4: 5 open-market purchases and 0 sales. Insiders bought $326.8 million and sold $0 worth of stock, for net insider buying of $326.8 million. The most recent filing shows Renaud Ronald C JR (CEO & President) reporting a transaction in 38,094 shares at $5.25 on Jun 9, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put KLRA's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
KLRA insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 9, 2026 | Renaud Ronald C JRCEO & President | Option exercise | 38,094 | $199.99K | Form 4 |
| Apr 20, 2026 | Kaplan Andrew T.Director | Buy | 8,398,438 | $134.38M | Form 4 |
| Apr 20, 2026 | Kaplan Andrew T.Director | Conversion | 17,857,143 | — | Form 4 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% Owner | Buy | 1,562,500 | $25.00M | Form 4 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% Owner | Conversion | 4,145,768 | — | Form 4 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% Owner | Conversion | 16,875,000 | — | Form 4 |
| Apr 20, 2026 | Koppel AdamDirector | Buy | 1,562,500 | $25.00M | Form 4 |
| Apr 20, 2026 | Koppel AdamDirector | Conversion | 4,145,768 | — | Form 4 |
| Apr 20, 2026 | Koppel AdamDirector | Conversion | 16,875,000 | — | Form 4 |
| Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC & Bain Capital XIV General Partner, LLC & Bain Capital Fund XIV, L.P. & BCPE Perseus Investor GP, LLC & BCPE Perseus Investor, LP10% Owner | Buy | 8,398,438 | $134.38M | Form 4 |
| Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC & Bain Capital XIV General Partner, LLC & Bain Capital Fund XIV, L.P. & BCPE Perseus Investor GP, LLC & BCPE Perseus Investor, LP10% Owner | Conversion | 17,857,143 | — | Form 4 |
| Apr 20, 2026 | RTW INVESTMENTS, LP & WONG RODERICK10% Owner | Buy | 500,000 | $8.00M | Form 4 |
| Apr 20, 2026 | RTW INVESTMENTS, LP & WONG RODERICK10% Owner | Conversion | 10,276,820 | — | Form 4 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner | Conversion | 2,034,133 | — | Form 4 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner | Conversion | 9,477,719 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4